CSF1R and colon carcinoma: Gyori et al. and colleagues reported similar findings in the MC38 colon carcinoma model, whereby T-cell-mediated control of tumour growth could only be achieved if treatment with the PI3Kδ inhibitor, Idelalisib, which resulted in reduced intra-tumoural Treg numbers, was combined with a CSF1R inhibitor to reduce numbers of tumour associated macrophages [32].